JPMorgan Sees ECB Raising Rates to 2.75% in December 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Singapore Straits Times Index Hits Record High as Banks, Property Stocks Rally 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Uranium Prices Could Top $100 as Nuclear Demand Grows 
Treasury Yields Set to Stay High as Debt Supply Pressures Bond Market 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Turkey Targets 5% Economic Growth by 2029 
Hong Kong Eyes Offshore Yuan Expansion, Deeper China Market Links 
U.S. Payrolls Seen Rebounding in August as Labor Market Stays Soft 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Asian Stocks Rally as Fed Rate Hike Fears Ease 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Asian Currencies Weaken as Dollar Rises, Kiwi Slides After RBNZ Hike 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Asian Stocks Rise as Bond Yields Ease, Oil Prices Stabilize 
Asian Currencies Rise as Yen Surges on Fed Rate Outlook 
Add as a preferred source on Google
Celltrion Inc., a biopharmaceutical company headquartered in Incheon, South Korea, is merging with its Celltrion Healthcare subsidiary in an effort to strengthen its business synergy or combined effort. The biosimilar producer and its biosimilar marketing unit are set to be consolidated this year.
Seo Jung Jin, Celltrion Group’s chairman, said on Thursday, Aug. 17, that once Celltrion is incorporated with Celltrion Healthcare, the newly-formed entity will also take in Celltrion Pharma. The chairman said this integration will eventually happen later but did not provide an exact time frame. After all the mergings, Celltrion, Celltrion Healthcare, and the company’s chemical pharma producer will work together as one.
According to The Korea Times, Celltrion revealed its plan to acquire Celltrion Healthcare during the company’s recent regulatory filing. The changes will also entail the issuance of new shares of Celltrion to shareholders of Celltrion Healthcare, and the merger ratio is expected to stand at 1:0.4492620.
It was mentioned that the Celltrion chairman holds a 95% stake in Celltrion Holdings which in turn holds a 20.02% stake in Celltrion. The holdings also have a 35.54% stake in Celltrion Healthcare and a 54.96% stake in Celltrion Pharm.
"Celltrion is expected to complete the merger of Celltrion Healthcare by the end of the year, followed by the next merger with Celltrion Pharm in the next six months," Seo Jung Jin shared during an online conference.
The Celltrion Group said it will merge the mentioned companies, but the plan still needs the approval of shareholders. This may be completed on October 23 at the shareholders' meeting. Celltrion and Celltrion Healthcare will eventually be dissolved after the merger.
To date, while the merger is still being processed, The Korea Herald reported that Celltrion is focusing on producing and developing bio-pharmaceutical products while Celltrion Healthcare is working more on selling these products.
Photo by: Celltrion Press Room
